# US 2026/0306600 A1 · Sarcoma cancer vaccines and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306600 A1
- Document ID: US20260306600A1
- Status: Published application
- Kind: A1
- Application number: 19/481,504
- Filed: 2024-05-03
- Published: 2026-10-08
- Earliest claimed: 2023-05-05
- Applicants: Memorial Sloan-Kettering Cancer Center; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Inventors: Christopher A. Klebanoff; Sandra D'Angelo
- Web page: https://patentgrep.com/patent/US20260306600A1

## CPC

- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 37/04: Immunostimulants
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides vaccine compositions comprising recombinant SS 18::SSX fusion peptide epitopes and at least one cancer-testis antigen (CTA) epitope, or nucleic acids (e.g., mRNA, cDNA) encoding the same, and methods for using the same to treat sarcoma (e.g., synovial sarcoma) in a subject in need thereof.

## Claims

### Claim 1

A vaccine comprising a polypeptide comprising at least one SS18::SSX fusion junction epitope and an oligomer of at least one cancer-testis antigen (CTA) epitope, wherein the at least one SS18::SSX fusion junction sequence comprises the amino acid sequence of PQQRPYGYDQIMPKKPAEDE (SEQ ID NO: 1), optionally wherein the at least one SS18::SSX fusion junction epitope is operably linked to the oligomer.

### Claim 2

A vaccine comprising a nucleic acid molecule encoding a polypeptide comprising at least one SS18::SSX fusion junction epitope and an oligomer of at least one cancer-testis antigen (CTA) epitope, wherein the at least one SS18::SSX fusion junction sequence comprises the amino acid sequence of PQQRPYGYDQIMPKKPAEDE (SEQ ID NO: 1), optionally wherein the at least one SS18::SSX fusion junction epitope is operably linked to the oligomer.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the at least one SS18::SSX fusion junction epitope is located at the N-terminus or the C-terminus of the oligomer.

### Claim 4 (depends on 1)

The vaccine of claim 1, wherein the at least one SS18::SSX fusion junction epitope comprises exon 10 or exon 11 of SS18 and exon 5 or exon 11 of SSX1 or SSX2.

### Claim 5 (depends on 1)

The vaccine of claim 1, wherein
the at least one CTA epitope is derived from one or more of NY-ESO-1, PRAME, or MAGEA4; or
the at least one CTA epitope comprises a NY-ESO-1 epitope comprising one or more amino acid sequences selected from among SLLMWITQC (SEQ ID NO: 2), LLMWITQCF (SEQ ID NO: 3), APRGPHGGAASGL (SEQ ID NO: 4), LEFYLAMPF (SEQ ID NO: 5) and ARGPESRLL (SEQ ID NO: 6); or
the at least one CTA epitope comprises a MAGE-A4 epitope comprising one or more amino acid sequences selected from among EVDPASNTY (SEQ ID NO: 7), GVYDGREHTV (SEQ ID NO: 8), and NYKRCFPVI (SEQ ID NO: 9); or
the at least one CTA epitope comprises a PRAME epitope comprising the amino acid sequence of ALYVDSLFFL (SEQ ID NO: 10); or
the oligomer is a dimer, a trimer, a tetramer, a pentamer, a hexamer, a heptamer, an octamer, a nonamer, a decamer, an 11-mer, a 12-mer, a 13-mer, a 14-mer, a 15-mer, a 16-mer, a 17-mer, an 18-mer, a 19-mer, a 20-mer, a 21-mer, a 22-mer, a 23-mer, a 24-mer, a 25-mer, a 26-mer, a 27-mer, a 28-mer, a 29-mer, or a 30-mer; or
the oligomer of the at least one CTA epitope comprises tandem repeats of a single CTA epitope, optionally wherein the tandem repeats of the single CTA epitope are linked via a linker; or
the oligomer of the at least one CTA epitope comprises at least 2 distinct CTA epitopes, optionally wherein the at least 2 distinct CTA epitopes are linked via a linker; or
the linker is a cleavable peptide linker or a rigid peptide linker; or
the oligomer of the at least one CTA epitope further comprises one or more sequences of any one of SEQ ID NOs: 2-10; or
the polypeptide further comprises a leader peptide at its N-terminus and an MHC class I trafficking signal (MITD) at its C terminus; or
the vaccine further comprises a pharmaceutically acceptable carrier selected from the group consisting of a cream, emulsion, gel, liposome, nanoparticle, or ointment; or
the vaccine is formulated within a nanoparticle, wherein the nanoparticle has a mean diameter of 50-200 nm; or
the SS18::SSX fusion junction epitope and/or the at least one CTA epitope are presented by one or more of HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-B*07:02, HLA-C*04:01, HLA-C*12:03, HLA-A *01:01 HLA-A *24:02 HLA-A *24:10 HLA-A *01:02 HLA-A *68:01, HLA-A *26:01 HLA-B*57:02, HLA-B*14:02, HLA-B* 35:01, HLA-B*38:01, HLA-B*41:01, HLA-B*49:01, HLA-B*39:06, HLA-B* 18:02, HLA-B*40:02, HLA-B*35:02, HLA-B*51:01, HLA-B*57:01, HLA-B*18:01, HLA-B*44:05, HLA-C*17:01, HLA-C*15:04, HLA-C*06:02, HLA-C*07:01, HLA-C* 02:02, HLA-C*03:04, HLA-C*07:02, HLA-C*08:02, or HLA-C*07:02.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 5)

The vaccine of claim 5, wherein the linker comprises a GS4 linker (SEQ ID NO: 13), a GS3 linker (SEQ ID NO: 14), a P2A linker, a T2A linker, an E2A linker, a F2A linker, a BmCPV2A linker, an AAY linker, a GPGPG linker (SEQ ID NO: 15), an EAAAK linker (SEQ ID NO: 16), a HEYGAEALERAG linker (SEQ ID NO: 17), a KK linker, or an RVRR linker (SEQ ID NO: 18).

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The vaccine of claim 2, wherein the nucleic acid molecule comprises RNA or DNA.

### Claim 17 (depends on 2)

The vaccine of claim 2, wherein the nucleic acid molecule comprises RNA, and wherein each uracil residue in the RNA comprises a chemical modification and/or at least one 5′ terminal cap.

### Claim 18 (depends on 17)

The vaccine of claim 17, wherein the chemical modification is in the 5-position of each uracil residue.

### Claim 19 (depends on 17)

The vaccine of claim 17, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-l-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2′-O-methyl uridine.

### Claim 20 (depends on 17)

The vaccine of claim 17, wherein the at least one 5′ terminal cap is a naturally occurring cap, a synthetic cap or an optimized cap.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 5)

The vaccine of claim 5, wherein the nanoparticle is a lipid nanoparticle.

### Claim 24 (depends on 23)

The vaccine of claim 23, wherein the nanoparticle has a polydiversity value of less than 0.4 or a net neutral charge at a neutral pH.

### Claim 25 (depends on 5)

The vaccine of claim 5, wherein the nanoparticle is a cationic lipid nanoparticle comprising a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid.

### Claim 26 (depends on 25)

The vaccine of claim 25, wherein the cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

### Claim 27 (depends on 25)

The vaccine of claim 25, wherein the cationic lipid nanoparticle has a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol; and about 0.5-15% PEG-modified lipid.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A method for preventing or treating sarcoma in a patient in need thereof comprising administering to the patient an effective amount of the vaccine of claim 1.

### Claim 30 (depends on 29)

The method of claim 29, wherein
the sarcoma is recurrent or metastatic; or
the patient has received at least one prior anti-cancer therapy, optionally wherein the at least one prior anti-cancer therapy is surgery, radiotherapy, or chemotherapy; or
the method further comprises sequentially, simultaneously or separately administering to the subject an effective amount of an immune checkpoint inhibitor; or
the patient harbors a loss-of-function in SETD2; or
the vaccine is administered pleurally, topically, parenterally, intramuscularly, intravenously, subcutaneously, intranodally, intratumorally, intrathecally, intrapleurally or intraperitoneally; or
the sarcoma is soft tissue sarcoma, synovial sarcoma, myxoid-round cell liposarcoma, malignant peripheral nerve sheath tumor, or undifferentiated pleiomorphic sarcoma.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 30)

The method of claim 30, wherein the immune checkpoint inhibitor comprises one or more of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-TIM3 antibody, an anti-4-1BB antibody, an anti-CD73 antibody, an anti-GITR antibody, and an anti-LAG-3 antibody; or wherein the immune checkpoint inhibitor is administered pleurally, topically, parenterally, intramuscularly, intravenously, subcutaneously, intranodally, intratumorally, intrathecally, intrapleurally or intraperitoneally.

### Claim 34 (depends on 33)

The method of claim 33, wherein
the anti-PD-L1 antibody comprises envafolimab, atezolizumab, avelumab, or durvalumab; or
wherein the anti-PD-1 antibody comprises pembrolizumab, nivolumab, or Cemiplimab; or
wherein the CTLA-4 antibody comprises ipilimumab or tremelimumab.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)
